Diarrhoeal Diseases (Updated February 2009)
References
[1] Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003;81: 197-204.
[2] WHO. Changing History. World Health Report 2004.
[3] United Nations. Millenium Development Goals Report. New York; 2005.
[4] Guerrant RL, Kosek M, Moore S, Lorntz B, Brantley R, Lima AA. Magnitude and impact of diarrheal diseases. Arch Med Res 2002;33: 351-5.
[5] Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine 2006;24:2732-50.
[6] Dougan G, Huett A, Clare S. Vaccines against human enteric bacterial pathogens. Br Med Bull 2002;62:113-23.ehYhtp//w.cinmnh.o/umd18289
[7] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-53.
[8] Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006;368:323-32.
[9] Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004;17:461-9.
[10] Lima AA. Tropical diarrhoea: new developments in traveller's diarrhoea. Curr Opin Infect Dis 2001;14:547-52.
[11] Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997;24 Suppl 1:S106-9.
[12] Sur D, Niyogi SK, Sur S, Datta KK, Takeda Y, Nair GB, et al. Multidrug-resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India? Emerg Infect Dis 2003;9:404-5.
[13] Krishna BV, Patil AB, Chandrasekhar MR. Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans R Soc Trop Med Hyg 2006;100:224-6.
[14] CDC. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 states, 2007. MMWR Morb Mortal Wkly Rep 2008;57:366-70.
[15] Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Chanock RM. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol 1972;10:1075-81.
[16] Glass RI, Noel J, Ando T, Fankhauser R, Belliot G, Mounts A, et al. The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis 2000;181 Suppl 2:S254-61.
[17] Estes MK, Prasad BV, Atmar RL. Noroviruses everywhere: has something changed? Curr Opin Infect Dis 2006;19:467-74.
[18] Dolin R. Noroviruses--challenges to control. N Engl J Med 2007;357:1072-3.
[19] Chimonas MA, Vaughan GH, Andre Z, Ames JT, Tarling GA, Beard S, et al. Passenger behaviors associated with norovirus infection on board a cruise ship--Alaska, May to June 2004. J Travel Med 2008;15:177-83.
[20] Greig JD, Lee MB. Enteric outbreaks in long-term care facilities and recommendations for prevention: a review. Epidemiol Infect 2008:1-11.
[21] Fankhauser RL, Noel JS, Monroe SS, Ando T, Glass RI. Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J Infect Dis 1998;178:1571-8.
[22] de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van Leusden F, et al. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol 2001;154:666-74.
[23] Buesa J, Collado B, Lopez-Andujar P, Abu-Mallouh R, Rodriguez Diaz J, Garcia Diaz A, et al. Molecular epidemiology of caliciviruses causing outbreaks and sporadic cases of acute gastroenteritis in Spain. J Clin Microbiol 2002;40:2854-9.
[24] Kageyama T, Shinohara M, Uchida K, Fukushi S, Hoshino FB, Kojima S, et al. Coexistence of multiple genotypes, including newly identified genotypes, in outbreaks of gastroenteritis due to Norovirus in Japan. J Clin Microbiol 2004;42:2988-95.
[25] Maunula L, Von Bonsdorff CH. Norovirus genotypes causing gastroenteritis outbreaks in Finland 1998-2002. J Clin Virol 2005;34:186-94.
[26] Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008;14:1224-31.
[27] Smit TK, Bos P, Peenze I, Jiang X, Estes MK, Steele AD. Seroepidemiological study of genogroup I and II calicivirus infections in South and southern Africa. J Med Virol 1999;59:227-31.
[28] Jing Y, Qian Y, Huo Y, Wang LP, Jiang X. Seroprevalence against Norwalk-like human caliciviruses in beijing, China. J Med Virol 2000;60:97-101.
[29] Okitsu-Negishi S, Nguyen TA, Phan TG, Ushijima H. Molecular epidemiology of viral gastroenteritis in Asia. Pediatr Int 2004;46:245-52.
[30] Green KY, Chanock RM, Kapikian AZ. Human caliciviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott , W.Wilkins, 2001.
[31] Nilsson M, Hedlund KO, Thorhagen M, Larson G, Johansen K, Ekspong A, et al. Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol 2003;77:13117-24.
[32] Phan TG, Kaneshi K, Ueda Y, Nakaya S, Nishimura S, Yamamoto A, et al. Genetic heterogeneity, evolution, and recombination in noroviruses. J Med Virol 2007;79:1388-400.
[33] Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J Infect Dis 1999;179:1334-44.
[34] Reuter G, Krisztalovics K, Vennema H, Koopmans M, Szucs G. Evidence of the etiological predominance of norovirus in gastroenteritis outbreaks--emerging new-variant and recombinant noroviruses in Hungary. J Med Virol 2005;76:598-607.
[35] Phan TG, Kuroiwa T, Kaneshi K, Ueda Y, Nakaya S, Nishimura S, et al. Changing distribution of norovirus genotypes and genetic analysis of recombinant GIIb among infants and children with diarrhea in Japan. J Med Virol 2006;78:971-8.
[36] Phan TG, Yan H, Li Y, Okitsu S, Muller WE, Ushijima H. Novel recombinant norovirus in China. Emerg Infect Dis 2006;12:857-8.
[37] Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008;5:e31.
[38] Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002;76:12335-43.
[39] Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002;185:1335-7.
[40] Huang P, Farkas T, Marionneau S, Zhong W, Ruvoen-Clouet N, Morrow AL, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003;188:19-31.
[41] Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003;9:548-53.
[42] Thorven M, Grahn A, Hedlund KO, Johansson H, Wahlfrid C, Larson G, et al. A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol 2005;79:15351-5.
[43] Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999;117:40-8.
[44] LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006;24:5220-34.
[45] Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000;182:302-5.
[46] Nataro JP, Barry EM. Diarrheal disease vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed: Saunders-Elsevier, 2008: 1163-71.
[47] Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human campylobacteriosis in developing countries. Emerg Infect Dis 2002;8:237-44.
[48] Fullerton KE, Ingram LA, Jones TF, Anderson BJ, McCarthy PV, Hurd S, et al. Sporadic campylobacter infection in infants: a population-based surveillance case-control study. Pediatr Infect Dis J 2007;26:19-24.
[49] Rivoal K, Ragimbeau C, Salvat G, Colin P, Ermel G. Genomic diversity of Campylobacter coli and Campylobacter jejuni isolates recovered from free-range broiler farms and comparison with isolates of various origins. Appl Environ Microbiol 2005;71:6216-27.
[50] Zweifel C, Scheu KD, Keel M, Renggli F, Stephan R. Occurrence and genotypes of Campylobacter in broiler flocks, other farm animals, and the environment during several rearing periods on selected poultry farms. Int J Food Microbiol 2008;125:182-7.
[51] Baqar S, Rice B, Lee L, Bourgeois AL, El Din AN, Tribble DR, et al. Campylobacter jejuni enteritis. Clin Infect Dis 2001;33:901-5.
[52] Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001;1:29-37.
[53] Baqar S, Applebee LA, Bourgeois AL. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect Immun 1995;63:3731-5.
[54] Lee LH, Burg E, 3rd, Baqar S, Bourgeois AL, Burr DH, Ewing CP, et al. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immun 1999;67:5799-805.
[55] Baqar S, Applebee LA, Gilliland TC, Jr., Lee LH, Porter CK, Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infect Immun 2008;76:3170-5.
[56] Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni mainly recognize conformational epitopes. FEMS Microbiol Lett 2007;272:137-43.
[57] Cholera, 2004. Wkly Epidemiol Rec 2005;80:261-8.
[58] Sack DA, Islam S, Brown KH, Islam A, Kabir AK, Chowdhury AM, et al. Oral therapy in children with cholera: a comparison of sucrose and glucose electrolyte solutions. J Pediatr 1980;96:20-5.
[59] Tacket CO, Sack DA. Cholera vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed: Saunders-Elsevier, 2008: 127-38.
[60] Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004;363:223-33.
[61] Koelle K, Rodo X, Pascual M, Yunus M, Mostafa G. Refractory periods and climate forcing in cholera dynamics. Nature 2005;436:696-700.
[62] Faruque SM, Naser IB, Islam MJ, Faruque AS, Ghosh AN, Nair GB, et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Natl Acad Sci U S A 2005;102:1702-7.
[63] Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, Mintz ED. Cholera in the United States, 1995-2000: trends at the end of the twentieth century. J Infect Dis 2001;184:799-802.
[64] World, Health, Oganization. Cholera, 2006. Wkly Epidemiol Rec 2007;82:273-84.
[65] Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 2007;7:521-30.
[66] Pancharoen C, Niwattanakanjana N, Mekmullica J, Chongsrisawat V. Hospital-based epidemiology of childhood cholera: a 6-year review in a university hospital in Bangkok, Thailand. J Med Assoc Thai 2004;87 Suppl 2:S59-61.
[67] WHO. Cholera unveiled. Global Task Force on Cholera Controll http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_ZFK_2003.3pdf.
[68] Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005;17:388-98.
[69] National, Travel, Health, Network, and, Centre. Travellers. Travel health information sheets. Cholera. http://www.nathnac.org/travel/factsheets/cholera.htm. [cited; Available from:
[70] Lonnroth I, Holmgren J. Subunit structure of cholera toxin. J Gen Microbiol 1973;76:417-27.
[71] Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 2000;31:561-5.
[72] Ivanoff B, Chaignat CL. [Anticholera vaccines and vaccination]. Bull Soc Pathol Exot 2002;95:355-8.
[73] Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991;338:1285-9.
[74] Lopez-Gigosos R, Garcia-Fortea P, Reina-Dona E, Plaza-Martin E. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS. Travel Med Infect Dis 2007;5:380-4.
[75] Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-3.
[76] van Loon FP, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996;14:162-6.
[77] Legros D, Paquet C, Perea W, Marty I, Mugisha NK, Royer H, et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull World Health Organ 1999;77:837-42.
[78] Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005;352:757-67.
[79] Ali M, Emch M, Yunus M, Sack D, Lopez AL, Holmgren J, et al. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J 2008;27:33-7.
[80] Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002;80:2-8.
[81] Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997;349:231-5.
[82] Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, Do GC, et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 2003;21:304-8.
[83] WHO. Initiative for Vaccine Research, WHO, Proceedings of the 7th Global Vaccine Research Forum. Bangkok; 2006.
[84] Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999;67:6341-5.
[85] Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000;18:2399-410.
[86] Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004;22:2444-51.
[87] Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005;73:3018-24.
[88] Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002;70:1965-70.
[89] Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005;192:573-9.
[90] Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007;25:8574-84.
[91] Ledon T, Valle E, Valmaseda T, Cedre B, Campos J, Rodriguez BL, et al. Construction and characterisation of O139 cholera vaccine candidates. Vaccine 2003;21:1282-91.
[92] Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci U S A 2007;104:10986-91.
[93] Perez JL, Acevedo R, Callico A, Fernandez Y, Cedre B, Ano G, et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 2009;27:205-12.
[94] Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines 2006;5:483-94.
[95] Karmali MA. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 2004;26:117-22.
[96] Konadu EY, Parke JC, Jr., Tran HT, Bryla DA, Robbins JB, Szu SC. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J Infect Dis 1998;177:383-7.
[97] Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 2005;18:465-83.
[98] Black RE. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 1993;11:100-6.
[99] Wenneras C, Erling V. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J Health Popul Nutr 2004;22:370-82.
[100] Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 2005;12:102-7.
[101] Niyogi SK. Shigellosis. J Microbiol 2005;43:133-43.
[102] Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, et al. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol 2003;41:4862-4.
[103] Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect Immun 2007;75:3961-8.
[104] Begum YA, Talukder KA, Nair GB, Khan SI, Svennerholm AM, Sack RB, et al. Comparison of enterotoxigenic Escherichia coli isolated from surface water and diarrhoeal stool samples in Bangladesh. Can J Microbiol 2007;53:19-26.
[105] Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990;12 Suppl 1:S73-9.
[106] Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis 2005;5:349-60.
[107] Flores J, DuPont HL, Lee SA, Belkind-Gerson J, Paredes M, Mohamed JA, et al. Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol 2008;15:1194-8.
[108] Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 1999;236:215-36.
[109] New frontiers in the development of vaccines against enterotoxinogenic (ETEC) and enterohaemorrhagic (EHEC) E. coli infections. Part I. Wkly Epidemiol Rec 1999;74:98-101.
[110] Ansaruzzaman M, Bhuiyan NA, Begum YA, Kuhn I, Nair GB, Sack DA, et al. Characterization of enterotoxigenic Escherichia coli from diarrhoeal patients in Bangladesh using phenotyping and genetic profiling. J Med Microbiol 2007;56:217-22.
[111] Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Molbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 2003;362:286-91.
[112] Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007;75:2163-70.
[113] Svennerholm AM, Tobias J. Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 2008;7:795-804.
[114] Boedeker EC. Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 2005;21:15-9.
[115] Svennerholm AM, Holmgren J. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Adv Exp Med Biol 1995;371B:1623-8.
[116] Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev Vaccines 2008;7:561-7.
[117] Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). J Travel Med 2000;7:27-9.
[118] Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007;25:4392-400.
[119] Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007;25:2545-66.
[120] Tobias J, Lebens M, Bolin I, Wiklund G, Svennerholm AM. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae. Vaccine 2008;26:743-52.
[121] McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun 2006;74:994-1000.
[122] Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, et al. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect Immun 2006;74:1062-71.
[123] Barry EM, Altboum Z, Losonsky G, Levine MM. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 2003; 21:333-40.
[124] Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 2006; 24:3727-34.
[125] Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, et al. Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 2007;25:4175-82.
[126] Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 2005;73:258-67.
[127] Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002;70:1874-80.
[128] McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007;25:3684-91.
[129] Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008;371:2019-25.
[130] Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 2004;22:4385-9.
[131] Clark HF, Offit PA, Parashar UD, Ward RL. Rotavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed: Saunders-Elsevier, 2008: 715-34.
[132] Parashar UD, Bresee JS, Glass RI. The global burden of diarrhoeal disease in children. Bull World Health Organ 2003;81:236.
[133] Widdowson MA, Bresee JS, Gentsch JR, Glass RI. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005;21:26-31.
[134] Parez N. Rotavirus gastroenteritis: why to back up the development of new vaccines? Comp Immunol Microbiol Infect Dis 2008;31:253-69.
[135] Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304-6.
[136] Gleizes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 2006;25:S12-21.
[137] Dennehy PH, Cortese MM, Begue RE, Jaeger JL, Roberts NE, Zhang R, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J 2006;25:1123-31.
[138] Anderson EJ, Weber SG. Rotavirus infection in adults. Lancet Infect Dis 2004;4:91-9.
[139] Marshall J, Botes J, Gorrie G, Boardman C, Gregory J, Griffith J, et al. Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged-care facilities. J Clin Virol 2003;28:331-40.
[140] Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004;22 Suppl 1:S49-54.
[141] Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
[142] Bresee J, Fang ZY, Wang B, Nelson EA, Tam J, Soenarto Y, et al. First report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 2004;10:988-95.
[143] Molbak K, Fischer TK, Mikkelsen CS. The estimation of mortality due to rotavirus infections in sub-Saharan Africa. Vaccine 2000;19:393-5.
[144] Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 2002;76:8110-7.
[145] Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005;15:29-56.
[146] Hoshino Y, Kapikian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr 2000;18:5-14.
[147] Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003;21:361-7.
[148] Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005;192 Suppl 1:S160-6.
[149] Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005;24:807-16.
[150] Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
[151] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354 :11-22.
[152] Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983;309:72-6.
[153] Barnes GL, Lund JS, Mitchell SV, De Bruyn L, Piggford L, Smith AL, et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002;20: 2950-6.
[154] Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin Microbiol Rev 1996;9:423-34.
[155] Dennehy PH. Rotavirus vaccines: an update. Curr Opin Pediatr 2005;17: 88-92.
[156] Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006;194:370-6.
[157] CDC. Withdrawal of rotavirus vaccine recommendation. MMWR, Morb Mortal Wkly Rep 1999;48:1007.
[158] Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
[159] Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007;26:221-7.
[160] Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 2006;24:5817-23.
[161] Banerjee I, Gladstone BP, Le Fevre AM, Ramani S, Iturriza-Gomara M, Gray JJ, et al. Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis 2007;195:625-32.
[162] Johansen K, Schroder U, Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 2003;21:368-75.
[163] Herrmann JE. DNA vaccines against enteric infections. Vaccine 2006;24:3705-8.
[164] Choi AH, Smiley K, Basu M. Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G). Vaccine 2005;23:2290-3.
[165] McNeal MM, Stone SC, Basu M, Bean JA, Clements JD, Hendrickson BA, et al. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology 2006;346:338-47.
[166] Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003;21:3885-900.
[167] Blutt SE, Warfield KL, O'Neal CM, Estes MK, Conner ME. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 2006;24:1170-9.
[168] Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 2006;80:1752-61.
[169] Glass RI, Bresee J, Jiang B, Parashar U, Yee E, Gentsch J. Rotavirus and rotavirus vaccines. Adv Exp Med Biol 2006;582:45-54.
[170] Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 2007;5:529-39.
[171] Dennehy PH. Rotavirus vaccines--an update. Vaccine 2007;25:3137-41.
[172] CDC. Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008;57:697-700.
[173] Shigellosis: disease burden, epidemiology and case management. Wkly Epidemiol Rec 2005;80:94-9.
[174] Levine OS, Levine MM. Houseflies (Musca domestica) as mechanical vectors of shigellosis. Rev Infect Dis 1991;13:688-96.
[175] Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis 2004;15:246-52.
[176] von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006;3:e353.
[177] Chompook P, Samosornsuk S, von Seidlein L, Jitsanguansuk S, Sirima N, Sudjai S, et al. Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bull World Health Organ 2005;83:739-46.
[178] Agtini MD, Soeharno R, Lesmana M, Punjabi NH, Simanjuntak C, Wangsasaputra F, et al. The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis 2005;5:89.
[179] Cossart P, Sansonetti PJ. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 2004;304:242-8.
[180] Cherla RP, Lee SY, Tesh VL. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003;228:159-66.
[181] Koterski JF, Nahvi M, Venkatesan MM, Haimovich B. Virulent Shigella flexneri causes damage to mitochondria and triggers necrosis in infected human monocyte-derived macrophages. Infect Immun 2005;73:504-13.
[182] Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007;5:540-53.
[183] Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992;47:276-83.
[184] Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, et al. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 2000;164:2221-32.
[185] Jennison AV, Verma NK. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 2004;28:43-58.
[186] World Health Organ. Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 2006;81:51-8.
[187] Kweon MN. Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 2008;21:313-8.
[188] Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996;64:4074-7.
[189] Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997;349:155-9.
[190] Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999;179:1565-8.
[191] Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 2003;22:701-6.
[192] Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001;69:1351-7.
[193] Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, et al. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Proc Natl Acad Sci U S A 2007;104:2396-401.
[194] Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M, et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J Immunol 2006;176:1686-94.
[195] Mel D, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Organ 1971;45:457-64.
[196] Levine MM, Gangarosa EJ, Barrow WB, Weiss CF. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease. Am J Epidemiol 1976;104:88-92.
[197] Venkatesan M, Fernandez-Prada C, Buysse JM, Formal SB, Hale TL. Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain. Vaccine 1991;9:358-63.
[198] Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004;72:923-30.
[199] Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, et al. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 2008;26:978-87.
[200] Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 2004;190:1745-54.
[201] Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007;3:268-75.
[202] Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005;73:8027-32.
[203] McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 2008;26:3291-6.
[204] Ranallo RT, Thakkar S, Chen Q, Venkatesan MM. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 2007;25:2269-78.
[205] McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006;24:3735-45.
[206] Kaminski RW, Turbyfill KR, Oaks EV. Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun 2006;74:2856-66.
[207] Oaks EV, Turbyfill KR. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 2006;24:2290-301.
[208] Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008;56:413-22.
[209] Parry CM. Typhoid Fever. Curr Infect Dis Rep 2004;6:27-33.
[210] Levine MM. Typhoid fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed: Saunders-Elsevier, 2008: 887-914.
[211] Parry C, Wain J, Chinh NT, Vinh H, Farrar JJ. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998;351:1289.
[212] Mermin JH, Villar R, Carpenter J, Roberts L, Samaridden A, Gasanova L, et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J Infect Dis 1999;179:1416-22.
[213] Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg 2004;98:423-30.
[214] Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82:346-53.
[215] Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005;11:326-9.
[216] DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med 2007;357:1069-71.
[217] Ochiai RL, Acosta CJ, Agtini M, Bhattacharya SK, Bhutta ZA, Do CG, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis 2007;45 Suppl 1:S34-8.
[218] Chaignat C, Clemens J, Favorov M, Klugman K, Kariuki S, Levine MM. Report of the Typhoid Immunization Group to SAGE. Geneva: WHO SAGE meeting; 2007 November 2007.
[219] Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004;39:186-91.
[220] Clemens J, Hoffman S, Ivanoff B, Klugman K, Levine MM, Neira M, et al. Typhoid fever vaccines. Vaccine 1999;17:2476-8.
[221] Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. Vaccine 2006;24:3804-11.
[222] DeRoeck D, Ochiai RL, Yang J, Anh DD, Alag V, Clemens JD. Typhoid vaccination: the Asian experience. Expert Rev Vaccines 2008;7:547-60.
[223] Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR, et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 2006;120:1081-7.
[224] Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J 2007;26:1001-5.
[225] Lim SM, Jung HS, Kim MJ, Park DW, Kim WJ, Cheong HJ, et al. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. J Microbiol Biotechnol 2007;17:611-5.
[226] Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996;14:435-8.
[227] Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999;18:609-20.
[228] Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001;79:625-31.
[229] Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999;67:5806-10.
[230] Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001;344:1263-9.
[231] Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999;17 Suppl 2:S22-7.
[232] Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007;45 Suppl 1:S24-8.
[233] Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002;26:339-53.
[234] Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996;173:1408-14.
[235] Witherell GW. Oral typhoid vaccine. Acambis/Berna. Curr Opin Investig Drugs 2003;4:1010-8.
[236] Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005;192:360-6.
[237] Lankowski AJ, Hohmann EL. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J Infect Dis 2007;195:1203-11.